Researchers from Drexel University and experts in aerospace engineering at ISAE-SUPAERO in Toulouse, France, found aircraft pilots commit more errors operating a real aircraft than a flight simulator by measuring brain activity using a portable, cognitive imaging system.

Two late-breaking clinical trials presented May 23 at EuroPCR in London demonstrated the ability of renal denervation to significantly lower patients’ blood pressures, regardless of whether they were taking antihypertensive medications.

The FlowTriever System has become the first thrombectomy device designed to treat pulmonary embolism (PE) to be cleared by the FDA, Inari Medical announced in a May 21 press release.

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

PARIS, May 22, 2018 — HeartFlow, Inc. today announced new data from the PACIFIC trial showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease (CAD), the most common form of heart disease, when compared to other commonly used non-invasive cardiac tests.

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

The FDA announced its approval of new patient Medication Guides for all gadolinium-based contrast agents (GBCAs) used for MRI, according to a recent press release.

Coronary CT angiography (CTA) is diagnostically accurate in detecting scaffold luminal obstruction, according to a team of international researchers, signaling it may become the preferred method for evaluating patients treated with bioresorbable vascular scaffold (BVS)—but not all experts agree.